Literature DB >> 19695066

Treatment of hyperlipidemic acute pancreatitis with plasma exchange: a single-center experience.

Jakob Gubensek1, Jadranka Buturović-Ponikvar, Andreja Marn-Pernat, Janko Kovac, Bojan Knap, Vladimir Premru, Rafael Ponikvar.   

Abstract

Of the cases of acute pancreatitis, 1-7% are caused by severe hypertriglyceridemia and can be treated with plasma exchange (PE). We report on a large series of patients with acute hyperlipidemic pancreatitis (HLP) treated with PE. In the 1992-2008 period, 50 patients (45 +/- 8 years old, 92% male) with acute HLP were treated with PE, during which 1-2 plasma volumes were exchanged. Heparin was used as anticoagulant in 85% of the procedures, and citrate in the rest. Cholesterol and triglycerides were measured before and after PE. In the 2003-2008 cohort of 40 patients, we retrospectively recorded an Acute Physiology and Chronic Health Evaluation II (APACHE II) score at the first PE session, hospital mortality, and length of hospital stay. A total of 79 PE treatments were done, 1-5 per patient. The volume exchanged was 4890 +/- 1300 mL over a duration of 3.5 +/- 2 h. During the first PE, the triglycerides were lowered from 58.9 +/- 40.8 to 10.8 +/- 10.8 mmol/L, and the total cholesterol was lowered from 20.0 +/- 7.6 to 5.7 +/- 4.3 mmol/L. In 10% of the procedures the plasmafilter was replaced, and in 3% the filter was clotted. Hypotension occurred in 3% of PE and there was one case of gastrointestinal bleeding after PE with heparin anticoagulation. In the 2003-2008 cohort, the median APACHE II score was 5 (range 0-15), the median overall hospital stay was 18 days (range 3-142 days) and the hospital mortality was 15%. To conclude, in acute hyperlipidemic pancreatitis, one to two plasma exchanges effectively reduce the serum triglyceride level. There is a low rate of procedure-related complications. A mortality rate of 15% is considerable.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19695066     DOI: 10.1111/j.1744-9987.2009.00731.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  8 in total

1.  PAN's labyrinth: a multidisciplinary delayed diagnosis and patient's perspective.

Authors:  Emma Louise Barlow; Owen Seddon; Brendan Healy
Journal:  BMJ Case Rep       Date:  2016-01-05

Review 2.  Issues in hypertriglyceridemic pancreatitis: an update.

Authors:  John Scherer; Vijay P Singh; C S Pitchumoni; Dhiraj Yadav
Journal:  J Clin Gastroenterol       Date:  2014-03       Impact factor: 3.062

Review 3.  Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis.

Authors:  Nils Ewald; Hans-Ulrich Kloer
Journal:  Clin Res Cardiol Suppl       Date:  2012-06

4.  Factors affecting outcome in acute hypertriglyceridemic pancreatitis treated with plasma exchange: an observational cohort study.

Authors:  Jakob Gubensek; Jadranka Buturovic-Ponikvar; Karmen Romozi; Rafael Ponikvar
Journal:  PLoS One       Date:  2014-07-21       Impact factor: 3.240

5.  Comparable Triglyceride Reduction With Plasma Exchange and Insulin in Acute Pancreatitis - A Randomized Trial.

Authors:  Jakob Gubensek; Milena Andonova; Alexander Jerman; Vanja Persic; Barbara Vajdic-Trampuz; Ana Zupunski-Cede; Nejc Sever; Samo Plut
Journal:  Front Med (Lausanne)       Date:  2022-04-12

6.  A Retrospective Research of the Characteristic of Hypertriglyceridemic Pancreatitis in Beijing, China.

Authors:  Wei-Ping Tai; Xiang-Chun Lin; Hong Liu; Cang-Hai Wang; Jing Wu; Neng-Wei Zhang; Wei Chen
Journal:  Gastroenterol Res Pract       Date:  2016-01-05       Impact factor: 2.260

Review 7.  Management of Hypertriglyceridemia Induced Acute Pancreatitis.

Authors:  Rajat Garg; Tarun Rustagi
Journal:  Biomed Res Int       Date:  2018-07-26       Impact factor: 3.411

8.  Hypertriglyceridaemia as a risk factor for critical care admission in acute pancreatitis: A prospective study.

Authors:  Alfred Adiamah; Anisa Kushairi; Sue Tumilty; Yuuki Na; Martin Crook; Adam J Brooks; Dileep N Lobo
Journal:  Clin Nutr ESPEN       Date:  2020-07-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.